IL-17A Blockade May Halt Spine Damage in AS (CME/CE)

(MedPage Today) -- Over 2 years, 80% of patients with ankylosing spondylitis treated with secukinumab had no progression
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news